CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity

Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis

(2016) Andreia M. Sousa et al.   APMIS

Pre-clinical toxicity and immunogenicity evaluation of a MUC1–MBP/BCG anti-tumor vaccine

(2016) Boqi Hu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

TLR9 played a more important role than TLR2 in the combination of maltose-binding protein and BCG-induced Th1 activation

(2016) Weihua Ni et al.   MOLECULAR IMMUNOLOGY

Update on Mucin-1 immunotherapy in cancer: a clinical perspective

(2015) Gareth Rivalland et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Escherichia coli maltose-binding protein (MBP) directly induces mouse Th1 activation through upregulating TLR2 and downregulating TLR4 expressions

(2015) Fang Wang et al.   IMMUNOBIOLOGY

Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis

(2015) Alan S. Cross et al.   VACCINE

Targeting the immune system to treat lung cancer: rationale and clinical experience

(2015) Nicolas Guibert et al.   Therapeutic Advances in Respiratory Disease

Escherichia coli maltose-binding protein activates mouse peritoneal macrophages and induces M1 polarization via TLR2/4 in vivo and in vitro

(2014) Weihua Ni et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Unknown

(2014) Xiaoling Gao et al.   MOLECULAR MEDICINE

MUC1 and maltose-binding protein recombinant fusion protein combined with Bacillus Calmette-Guerin induces MUC1-specific and nonspecific anti-tumor immunity in mice

(2014) FANG FANG et al.   Molecular Medicine Reports

The mechanism of action of BCG therapy for bladder cancer—a current perspective

(2014) Gil Redelman-Sidi et al.   Nature Reviews Urology

MUC1: a multifaceted oncoprotein with a key role in cancer progression

(2014) Sritama Nath et al.   TRENDS IN MOLECULAR MEDICINE

Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)

(2014) Jacob T. Minang et al.   VACCINE

Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist

(2014) L. Fend et al.   Cancer Immunology Research

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

(2013) Maurizio Brausi et al.   EUROPEAN UROLOGY

Dendritic-Cell-Based Therapeutic Cancer Vaccines

(2013) Karolina Palucka et al.   IMMUNITY

Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial

(2010) Ole S. Søgaard et al.   CLINICAL INFECTIOUS DISEASES

MUC1 immunotherapy

(2010) Richard E Beatson et al.   Immunotherapy

TLR-based immune adjuvants

(2010) Folkert Steinhagen et al.   VACCINE

CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases

(2009) Dennis M. Klinman et al.   ADVANCED DRUG DELIVERY REVIEWS

Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

(2009) John A. Thompson et al.   Clinical Genitourinary Cancer

Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1

(2008) C. Ding et al.   BLOOD